Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy

Shin Young Jeong, Sang-Woo Lee, Wan Wook Kim, Jin Hyang Jung, Won Kee Lee, Byeong-Cheol Ahn, Jaetae Lee, Shin Young Jeong, Sang-Woo Lee, Wan Wook Kim, Jin Hyang Jung, Won Kee Lee, Byeong-Cheol Ahn, Jaetae Lee

Abstract

We aimed to determine whether recombinant human thyrotropin (rhTSH) plus 3.7 GBq could replace thyroid hormone withdrawal (THW) plus 5.55 GBq for adjuvant radioactive iodine (RAI) therapy in differentiated thyroid cancer (DTC) patients with T4 or N1b disease. This study was a retrospective study comparing ablation success rate, response to initial therapy, and recurrence-free survival (RFS) of patients with rhTSH plus 3.7 GBq versus those with THW plus 5.55 GBq in 253 DTC patients with T4 or N1b disease. There were no differences in the TSH-stimulated thyroglobulin level, rate of incomplete response after initial treatment, or the RFS between the two treatment strategies. However, thyroid bed uptake on follow-up diagnostic RAI whole-body scanning (WBS) was more frequently observed in the group treated with rhTSH plus 3.7 GBq than in the group with THW plus 5.55 GBq. Adjuvant RAI therapy with rhTSH plus 3.7 GBq had comparable results in the absence of persistent tumor, compared with that with THW plus 5.55 GBq. Although thyroid bed uptake was more frequently observed, rhTSH plus 3.7 GBq may be used instead of THW plus 5.55 GBq for adjuvant RAI therapy in patients with T4 or N1b disease.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Kaplan-Meier analysis of recurrence-free survival according to adjuvant radioactive iodine (RAI) therapy strategies; THW plus 5.5 GBq of RAI and rhTSH plus 3.7 GBq of RAI.

References

    1. Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. doi: 10.1089/thy.2015.0020.
    1. Kloos RT, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J. Clin. Endocrinol. Metab. 2002;87:5817–5820. doi: 10.1210/jc.2002-020210.
    1. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13:265–271. doi: 10.1089/105072503321582060.
    1. Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary Gland Function 5 Years After Radioactive Iodine Ablation in Patients with Differentiated Thyroid Cancer: Direct Comparison of Pre- and Postablation Scintigraphies and Their Relation to Xerostomia Symptoms. Thyroid. 2013;23:609–616. doi: 10.1089/thy.2012.0106.
    1. Schroeder PR, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 2006;91:878–884. doi: 10.1210/jc.2005-2064.
    1. Hänscheid H, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J. Nucl. Med. 2006;47:648–654.
    1. Mallick U, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 2012;366:1674–1685. doi: 10.1056/NEJMoa1109589.
    1. Schlumberger M, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 2012;366:1663–1673. doi: 10.1056/NEJMoa1108586.
    1. Hugo J, et al. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid. 2012;10:1007–15. doi: 10.1089/thy.2012.0183.
    1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid19, 1167–1214 (2009).
    1. Sawka AM, et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 2004;89:3668–3676. doi: 10.1210/jc.2003-031167.
    1. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J. Clin. Endocrinol. Metab. 2007;92:28–38. doi: 10.1210/jc.2006-1345.
    1. van der Horst-Schrivers AN, et al. Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success–an observational study. PLoS One. 2015;20:e0120184. doi: 10.1371/journal.pone.0120184.
    1. Bartenstein P, et al. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Thyroid. 2014;24:480–487. doi: 10.1089/thy.2013.0157.
    1. Sabra MM, Grewal RK, Ghossein RA, Tuttle RM. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. Thyroid. 2014;24:1088–1095. doi: 10.1089/thy.2013.0465.
    1. Verburg FA, Mäder U, Reiners C, Hänscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. J Clin Endocrinol Metab. 2014;99:487–496. doi: 10.1210/jc.2014-1631.
    1. Lim DJ, et al. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin. Korean J. Intern. Med. 2010;25:408–414. doi: 10.3904/kjim.2010.25.4.408.
    1. Borget I, et al. Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. J. Clin. Oncol. 2015;33:2885–2892. doi: 10.1200/JCO.2015.61.6722.
    1. Pujol P, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996;81:4318–23.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit